Aquinox Pharmaceuticals Inc. (AQXP) Sees Large Volume Increase
Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP) saw an uptick in trading volume on Friday . 157,593 shares traded hands during mid-day trading, a decline of 7% from the previous session’s volume of 169,820 shares.The stock last traded at $6.93 and had previously closed at $6.97.
Several brokerages recently issued reports on AQXP. Leerink Swann dropped their target price on shares of Aquinox Pharmaceuticals from $26.00 to $21.00 and set an “outperform” rating on the stock in a report on Wednesday, March 16th. Needham & Company LLC began coverage on shares of Aquinox Pharmaceuticals in a report on Thursday, May 12th. They issued a “buy” rating and a $25.00 target price on the stock. Finally, Jefferies Group restated a “hold” rating and issued a $9.00 target price (down previously from $19.00) on shares of Aquinox Pharmaceuticals in a report on Tuesday, March 15th. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. Aquinox Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $19.86.
The company has a 50-day moving average of $7.17 and a 200-day moving average of $8.99. The stock’s market capitalization is $121.34 million.
Aquinox Pharmaceuticals (NASDAQ:AQXP) last issued its quarterly earnings results on Tuesday, May 10th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by $0.04. Equities research analysts forecast that Aquinox Pharmaceuticals Inc. will post ($1.79) earnings per share for the current year.
A hedge fund recently bought a new stake in Aquinox Pharmaceuticals stock. Numeric Investors LLC acquired a new position in Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 185,810 shares of the company’s stock, valued at approximately $2,319,000. Numeric Investors LLC owned approximately 1.08% of Aquinox Pharmaceuticals at the end of the most recent reporting period.
Aquinox Pharmaceuticals, Inc, formerly Aquinox Pharmaceuticals (USA) Inc, is a clinical stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. Aquinox Pharmaceuticals (Canada) Inc is a wholly owned subsidiary of the Company.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.